FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2608485495> ?p ?o ?g. }

• W2608485495 endingPage "44185" @default.
• W2608485495 startingPage "44171" @default.
• W2608485495 abstract "Clinical treatment for colorectal cancer (CRC) thus far encounters a huge challenge due to oxaliplatin-resistance. As crucial rate-limiting enzymes in aerobic glycolysis and glutaminolysis, pyruvate kinase M2 type (PKM2) and kidney-type glutaminase (GLS1) are proposed to carry important implications in colorectal carcinogenesis and drug-resistance. This study aimed to explore the possible association of oxaliplatin-resistance with aerobic glycolysis/glutaminolysis indexed by PKM2/GLS1 expression. PKM2 and GLS1 expression was quantified by polymerase chain reaction (PCR) and Western blot techniques in CRC cell lines. The abilities of cell formation, kinetics, migration, invasion, survival and apoptosis, as well as permeability glycoprotein (Pgp) expression were inspected before and after knocking-down PKM2/GLS1 expression. In addition, the influence of knocking-down PKM2/GLS1 expression was evaluated in vivo. Differentiated PKM2 and GLS1 expression in both THC8307 and THC8307/Oxa cell lines was identified. In the THC8307 cell line, PKM2 and GLS1 can accelerate malignant behaviors, increase oxaliplatin-resistance, upregulate Pgp expression, and inhibit cell apoptosis. Contrastingly in the THC8307/Oxa cell line, knockdown of PKM2/GLS1 expression can restrain malignant behaviors, reestablish oxaliplatin-sensitivity, downregulate Pgp expression, and induce cell apoptosis. In xenograft, knockdown of PKM2/GLS1 expression can significantly inhibit tumor growth, reduce Pgp expression, and increase tumor apoptosis. Taken together, the present findings enriched our knowledge by demonstrating a significant association of PKM2 and GLS1 with oxaliplatin-resistance in CRC. We further propose that knockdown of PKM2/GLS1 expression may constitute a novel therapeutic strategy toward effective treatment for CRC." @default.
• W2608485495 created "2017-05-05" @default.
• W2608485495 creator A5007219656 @default.
• W2608485495 creator A5056595224 @default.
• W2608485495 creator A5078840423 @default.
• W2608485495 creator A5084309435 @default.
• W2608485495 date "2017-04-24" @default.
• W2608485495 modified "2023-10-11" @default.
• W2608485495 title "Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells" @default.
• W2608485495 cites W1515331240 @default.
• W2608485495 cites W1635741485 @default.
• W2608485495 cites W1866746139 @default.
• W2608485495 cites W1973304708 @default.
• W2608485495 cites W1980247729 @default.
• W2608485495 cites W2016277931 @default.
• W2608485495 cites W2019808918 @default.
• W2608485495 cites W2031127086 @default.
• W2608485495 cites W2031628684 @default.
• W2608485495 cites W2054249720 @default.
• W2608485495 cites W2090406819 @default.
• W2608485495 cites W2097259163 @default.
• W2608485495 cites W2102089888 @default.
• W2608485495 cites W2120245271 @default.
• W2608485495 cites W2128403792 @default.
• W2608485495 cites W2132117833 @default.
• W2608485495 cites W2146253536 @default.
• W2608485495 cites W2146356730 @default.
• W2608485495 cites W2154387196 @default.
• W2608485495 cites W2156402278 @default.
• W2608485495 cites W2158030631 @default.
• W2608485495 cites W2170914411 @default.
• W2608485495 cites W2203864094 @default.
• W2608485495 cites W2235523093 @default.
• W2608485495 cites W2253669619 @default.
• W2608485495 cites W2255621879 @default.
• W2608485495 cites W2272984102 @default.
• W2608485495 cites W2279664546 @default.
• W2608485495 cites W2412307969 @default.
• W2608485495 cites W2460595841 @default.
• W2608485495 cites W2479476988 @default.
• W2608485495 cites W2482611486 @default.
• W2608485495 cites W2509807552 @default.
• W2608485495 cites W2516762816 @default.
• W2608485495 cites W2540391384 @default.
• W2608485495 cites W2554062701 @default.
• W2608485495 cites W2557380307 @default.
• W2608485495 cites W2561099695 @default.
• W2608485495 doi "https://doi.org/10.18632/oncotarget.17396" @default.
• W2608485495 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5546471" @default.
• W2608485495 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28498807" @default.
• W2608485495 hasPublicationYear "2017" @default.
• W2608485495 type Work @default.
• W2608485495 sameAs 2608485495 @default.
• W2608485495 citedByCount "36" @default.
• W2608485495 countsByYear W26084854952018 @default.
• W2608485495 countsByYear W26084854952019 @default.
• W2608485495 countsByYear W26084854952020 @default.
• W2608485495 countsByYear W26084854952021 @default.
• W2608485495 countsByYear W26084854952022 @default.
• W2608485495 countsByYear W26084854952023 @default.
• W2608485495 crossrefType "journal-article" @default.
• W2608485495 hasAuthorship W2608485495A5007219656 @default.
• W2608485495 hasAuthorship W2608485495A5056595224 @default.
• W2608485495 hasAuthorship W2608485495A5078840423 @default.
• W2608485495 hasAuthorship W2608485495A5084309435 @default.
• W2608485495 hasBestOaLocation W26084854951 @default.
• W2608485495 hasConcept C10730799 @default.
• W2608485495 hasConcept C121608353 @default.
• W2608485495 hasConcept C126322002 @default.
• W2608485495 hasConcept C143998085 @default.
• W2608485495 hasConcept C173396325 @default.
• W2608485495 hasConcept C20251656 @default.
• W2608485495 hasConcept C2780854706 @default.
• W2608485495 hasConcept C2780962732 @default.
• W2608485495 hasConcept C502942594 @default.
• W2608485495 hasConcept C526805850 @default.
• W2608485495 hasConcept C54355233 @default.
• W2608485495 hasConcept C62231903 @default.
• W2608485495 hasConcept C71924100 @default.
• W2608485495 hasConcept C81885089 @default.
• W2608485495 hasConcept C86803240 @default.
• W2608485495 hasConceptScore W2608485495C10730799 @default.
• W2608485495 hasConceptScore W2608485495C121608353 @default.
• W2608485495 hasConceptScore W2608485495C126322002 @default.
• W2608485495 hasConceptScore W2608485495C143998085 @default.
• W2608485495 hasConceptScore W2608485495C173396325 @default.
• W2608485495 hasConceptScore W2608485495C20251656 @default.
• W2608485495 hasConceptScore W2608485495C2780854706 @default.
• W2608485495 hasConceptScore W2608485495C2780962732 @default.
• W2608485495 hasConceptScore W2608485495C502942594 @default.
• W2608485495 hasConceptScore W2608485495C526805850 @default.
• W2608485495 hasConceptScore W2608485495C54355233 @default.
• W2608485495 hasConceptScore W2608485495C62231903 @default.
• W2608485495 hasConceptScore W2608485495C71924100 @default.
• W2608485495 hasConceptScore W2608485495C81885089 @default.
• W2608485495 hasConceptScore W2608485495C86803240 @default.
• W2608485495 hasIssue "27" @default.
• W2608485495 hasLocation W26084854951 @default.

• next